Advances in Hematology and Oncology Research(AHOR)
ISSN: 2692-5516 | DOI: 10.33140/AHOR
Impact Factor: 1.2
Vishnu Priya M
Clinical Pharmacology, HCG Cancer Hospital, India
Publications
-
Research Article
Oral Domiciliary Therapy of Multiple Myeloma with Cyclophosphamide, Pomalidomide and Dexamethasone Regimen in the Covid Era - A Pilot Study
Author(s): Sachin Suresh Jadhav*, Vishnu Priya M, Jyothi Goutham Kumar, Anjali Matani, Amey C Panchal and Nishit
Background: Multiple myeloma is the 11th most common cancer in India, with a prevalence of 1.1% and a diagnosis age range of 65 to 74 years. Various doublet or triplet combinations of steroids, immunomodulatory medications, proteasome inhibitors, and monoclonal antibodies are used in standard myeloma therapy. Covid 19 pandemic has been extremely challenging especially when it comes to the management of cancer patients. As the incidence of multiple myeloma (MM) is increasing rapidly in Asian countries, and the Asian patients seem to respond differently compared to the western population to the various commonly used treatment regimens, these patients require special consideration and care to ensure optimum treatment and at the same time, precautions must be taken to decrease their exposure to COVID-19. Considering these aspects, we decided to use an all-oral treatment o.. Read More»